Study Results on Cardiovascular Risks for Obesity Drug May be “Unreliable,” FDA Says
Study results showing that Orexigen’s obesity drug Contrave reduced the risk of heart attacks were probably “unreliable,” “misleading,” and “likely false,” according to a top official at the Food and Drug Administration (FDA). Orexigen released the Contrave data as part of a patent filing with the Securities and Exchange … [Read more...] about Study Results on Cardiovascular Risks for Obesity Drug May be “Unreliable,” FDA Says
Medtronic Agrees to Pay $2.8 Million to Settle False Claims
$2.8 Million to Settle False Claims. Medtronic has agreed to pay $2.8 million to settle allegations under the False Claims Act. According to a news release from the Department of Justice (DOJ), the company allegedly caused some doctors to submit false claims to federal health care programs for SubQ stimulation. SubQ stimulation … [Read more...] about Medtronic Agrees to Pay $2.8 Million to Settle False Claims
